Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antiplatelet therapy: views from the experts.

J D Easton1, H C Diener, N M Bornstein

  • 1Department of Clinical Neurosciences, Brown University School of Medicine, Rhode Island Hospital, Providence 02903, USA.

Neurology
|October 26, 1999
PubMed
Summary

Low-dose aspirin is generally as effective as high-dose aspirin for stroke prevention and improves patient compliance. New antiplatelet agents offer alternatives, but direct comparisons are needed for optimal patient care.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Placebo Response in Acute and Prophylactic Treatment of Migraine: A Systematic Review and Meta-Analysis Covering 36 Years of Research.

Neurologic clinics·2025
Same author

[Diagnosis and treatment of acute ischemic insults].

Herz·2021
Same author

European Academy of Neurology guideline on the management of medication-overuse headache.

European journal of neurology·2020
Same author

MMW Fortschritte der Medizin·2018
Same author

Preventing dementia beyond treating hypertension.

European heart journal·2018
Same author

MMW Fortschritte der Medizin·2018

Area of Science:

  • Neurology
  • Pharmacology

Background:

  • Antiplatelet therapy is crucial for preventing recurrent thromboembolic stroke and transient ischemic attack (TIA) not of cardiac origin.
  • Aspirin remains the most common preventive treatment for ischemic stroke, but optimal dosing for cerebrovascular disease is debated.

Framework:

  • Low-dose aspirin is considered equally effective to high-dose aspirin by experts, with improved tolerability potentially enhancing long-term compliance.
  • Higher aspirin doses may offer benefits in specific scenarios, warranting further investigation.

Implementation:

  • Aspirin serves as the benchmark for comparing newer antiplatelet agents.
  • Newer antiplatelet drugs have demonstrated efficacy against aspirin in trials, but direct comparative data among them is limited.

Related Experiment Videos

Implications:

  • Clinical decisions for long-term antiplatelet therapy in cerebrovascular disease are complex due to the lack of head-to-head trials of alternative agents.
  • Stroke neurologists prioritize drug efficacy, safety, and availability when selecting antiplatelet treatments for patients with a history of TIA or stroke.